Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $5.00 Average Price Target from Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have earned an average rating of “Hold” from the six research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $5.00.

Several equities research analysts recently commented on the stock. Morgan Stanley cut their price target on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, November 12th. Wedbush reissued a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $2.47 on Friday. The stock has a market capitalization of $178.46 million, a PE ratio of -1.19 and a beta of 1.72. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $3.95. The business has a 50 day simple moving average of $2.32 and a 200-day simple moving average of $1.81.

Insider Transactions at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters purchased 6,459,973 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the completion of the transaction, the insider owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. This trade represents a 91.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $1.33, for a total value of $9,975,000.00. Following the completion of the transaction, the insider owned 6,459,973 shares in the company, valued at $8,591,764.09. The trade was a 53.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 7,546,617 shares of company stock valued at $10,088,417 over the last ninety days. Insiders own 1.90% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC grew its stake in Zentalis Pharmaceuticals by 177.6% during the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock valued at $985,000 after acquiring an additional 396,233 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares during the last quarter. Tybourne Capital Management HK Ltd. grew its position in shares of Zentalis Pharmaceuticals by 53.7% in the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock valued at $1,715,000 after purchasing an additional 516,666 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $38,000. Finally, Savant Capital LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $59,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.